ATARA BIOTHERAPEUTICS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$4.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$4.83M, a 302.51% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$4.14M, a 110.91% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$3.41M.
- ATARA BIOTHERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$4.30M.
- ATARA BIOTHERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was $32.69M.
- ATARA BIOTHERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$85.40M.
- ATARA BIOTHERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$276.13M.
- ATARA BIOTHERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$228.30M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.83M 10-Q · filed 2026-08-12 | -$8.98M 10-Q · filed 2026-08-12 | -$12.38M derived: sum of 3 quarters · filed 2026-08-12 | -$16.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$4.14M 10-Q · filed 2026-05-12 | -$7.55M derived: sum of 2 quarters · filed 2026-05-12 | -$11.85M derived: sum of 3 quarters · filed 2026-05-12 | -$9.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$3.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$7.71M derived: sum of 2 quarters · filed 2026-03-16 | -$5.32M derived: sum of 3 quarters · filed 2026-08-12 | $32.69M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$4.30M 10-Q · filed 2025-11-12 | -$1.92M derived: sum of 2 quarters · filed 2026-08-12 | $36.09M 10-Q · filed 2025-11-12 | $23.40M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.39M 10-Q · filed 2026-08-12 | $40.40M 10-Q · filed 2026-08-12 | $27.70M derived: sum of 3 quarters · filed 2026-08-12 | $5.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $38.01M 10-Q · filed 2026-05-12 | $25.32M derived: sum of 2 quarters · filed 2026-05-12 | $3.41M derived: sum of 3 quarters · filed 2026-05-12 | -$15.64M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$12.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$34.60M derived: sum of 2 quarters · filed 2026-03-16 | -$53.65M derived: sum of 3 quarters · filed 2026-03-16 | -$85.40M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$21.91M 10-Q · filed 2025-11-12 | -$40.96M derived: sum of 2 quarters · filed 2025-11-12 | -$72.71M 10-Q · filed 2025-11-12 | -$133.16M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$19.05M 10-Q · filed 2025-08-11 | -$50.80M 10-Q · filed 2025-08-11 | -$111.25M derived: sum of 3 quarters · filed 2025-08-11 | -$181.05M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$31.75M 10-Q · filed 2025-05-15 | -$92.20M derived: sum of 2 quarters · filed 2025-05-15 | -$162.00M derived: sum of 3 quarters · filed 2025-05-15 | -$233.11M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$60.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$130.25M derived: sum of 2 quarters · filed 2025-03-07 | -$201.35M derived: sum of 3 quarters · filed 2025-03-07 | -$276.13M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$69.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$140.91M derived: sum of 2 quarters · filed 2024-11-12 | -$215.68M 10-Q · filed 2024-11-12 | -$290.25M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$71.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$145.88M 10-Q · filed 2024-08-12 | -$220.45M derived: sum of 3 quarters · filed 2024-08-12 | -$304.54M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$74.77M 10-Q · filed 2024-05-09 | -$149.34M derived: sum of 2 quarters · filed 2024-05-09 | -$233.43M derived: sum of 3 quarters · filed 2024-05-09 | -$214.97M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$74.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$158.66M derived: sum of 2 quarters · filed 2024-03-28 | -$140.20M derived: sum of 3 quarters · filed 2024-03-28 | -$228.30M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$84.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$65.63M derived: sum of 2 quarters · filed 2023-11-01 | -$153.73M 10-Q · filed 2023-11-01 | -$247.08M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $18.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$69.64M 10-Q · filed 2023-08-08 | -$162.99M derived: sum of 3 quarters · filed 2023-08-08 | -$247.65M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$88.11M 10-Q · filed 2023-05-08 | -$181.45M derived: sum of 2 quarters · filed 2023-05-08 | -$266.12M derived: sum of 3 quarters · filed 2023-05-08 | -$349.91M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$93.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | -$178.01M derived: sum of 2 quarters · filed 2023-02-08 | -$261.81M derived: sum of 3 quarters · filed 2023-02-08 | -$340.14M 10-K · filed 2023-02-08 |
| 2021-09-30 | -$84.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$168.46M derived: sum of 2 quarters · filed 2022-11-08 | -$246.79M 10-Q · filed 2022-11-08 | -$328.10M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-06-30 | -$83.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$162.13M 10-Q · filed 2022-08-08 | -$243.44M derived: sum of 3 quarters · filed 2023-02-08 | -$317.78M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-03-31 | -$78.33M 10-Q · filed 2022-05-05 | -$159.64M derived: sum of 2 quarters · filed 2023-02-08 | -$233.99M derived: sum of 3 quarters · filed 2023-02-08 | -$311.45M derived: sum of 4 quarters · filed 2023-02-08 |
| 2020-12-31 | -$81.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | -$155.66M derived: sum of 2 quarters · filed 2023-02-08 | -$233.11M derived: sum of 3 quarters · filed 2023-02-08 | -$306.62M 10-K · filed 2023-02-08 |
| 2020-09-30 | -$74.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$151.80M derived: sum of 2 quarters · filed 2021-11-04 | -$225.31M 10-Q · filed 2021-11-04 | -$303.81M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$77.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$150.97M 10-Q · filed 2021-08-09 | -$229.46M derived: sum of 3 quarters · filed 2022-02-28 | -$301.36M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$73.51M 10-Q · filed 2021-05-04 | -$152.00M derived: sum of 2 quarters · filed 2022-02-28 | -$223.90M derived: sum of 3 quarters · filed 2022-02-28 | -$298.23M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$78.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$150.39M derived: sum of 2 quarters · filed 2022-02-28 | -$224.72M derived: sum of 3 quarters · filed 2022-02-28 | -$290.98M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$71.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$146.22M derived: sum of 2 quarters · filed 2020-11-09 | -$212.48M 10-Q · filed 2020-11-09 | -$292.49M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$74.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$140.59M 10-Q · filed 2020-08-05 | -$220.60M derived: sum of 3 quarters · filed 2021-03-01 | -$278.96M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$66.26M 10-Q · filed 2020-05-06 | -$146.27M derived: sum of 2 quarters · filed 2021-03-01 | -$204.63M derived: sum of 3 quarters · filed 2021-03-01 | -$255.51M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$80.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$138.37M derived: sum of 2 quarters · filed 2021-03-01 | -$189.26M derived: sum of 3 quarters · filed 2021-03-01 | -$230.70M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$58.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$109.24M derived: sum of 2 quarters · filed 2019-11-07 | -$150.69M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | -$50.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$92.33M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | -$41.44M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | -$119.49M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | -$79.05M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |